Full-Life Technologies announced that the company has presented the preclinical data of ²²⁵Ac-FL-020 (a PSMA-targeted RDC program) at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.

Gembloux, Belgium – Mar. 26, 2024 – Full-Life Technologies (“Full-Life”), today announced the recent achievement of its subsidiary “Full-Life Technology Europe” has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control (“FANC”).

Shanghai, China, and Heidelberg, Germany – Mar. 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that preclinical data of ²²⁵Ac-FL-020 (a PSMA-targeted RDC program) will be presented in a Poster Session at the AACR (American Association for Cancer Research) Annual Meeting 2024.

Gembloux, Belgium and Berlin, Germany – Jan. 23, 2024 – Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company and Eckert & Ziegler (ISIN DE0005659700, SDAX) today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225).

Shanghai, Gembloux, Belgium, and Heidelberg, Germany - Jan. 4, 2024 - Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.